ST-Segment Elevation Myocardial Infarction (Lytic Candidate) on Oral Anticoagulant
Patients on oral anticoagulation who present with a ST-segment myocardial infarction and require fibrinolytics therapy represent a high patient population. With limited evidence to guide management, providers must assess risk versus benefit and attempt to mitigate bleeding events.
KeywordsFibrinolytics STEMI Bleeding Door-to-needle Risk assessment Hemorrhage
- 2.Lip GYH, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Intervention (EAPCI), and the European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35(45):3155–79.CrossRefPubMedGoogle Scholar
- 4.Bovill E, Terrin M, Stump D, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infraction (TIMI) phase II trial. Ann Intern Med. 1991;115(4):256–65.CrossRefPubMedGoogle Scholar
- 7.Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47:581–641.CrossRefPubMedGoogle Scholar